BRIDGEWATER, NJ, January 28, 2008 - A new brochure on the PROLOC(TM) Bioadhesive
Drug Delivery System, a new bioadhesive technology from the Transdermal
business group of National Adhesives, has been published.
The PROLOC(TM) Bioadhesive Drug Delivery System provides the means to deliver
drugs locally or systemically from various mucosal absorption sites on the
body. According to National Adhesives officials, several successful clinical
trials have been completed to support the delivery of drugs across the mucosa
using this novel technology. These clinical trials include successful delivery
via buccal, vaginal, ocular and nasal absorption sites and have involved drugs
such as Nystatin and Metronidazole.
The brochure includes charts that illustrate clinical data on a multitude of
applications, including in vivo adhesion time in dogs, irritation indices,
buccal tablet for testosterone delivery in dogs, buccal tablet for Nystatin
delivery in human voice box prothesis, vaginal tablet for Metronidazole
delivery in humans, mean serum concentrations and nasal delivery of insulin in
PROLOC is a proprietary technology providing superior bioadhesive properties
with the capacity for high drug loading. The proprietary process, which does
not create a new chemical entity, incorporates a USP-grade polysaccharide and
polycarboxylated polymer and is effective as a sustained or controlled release
preparation with an active agent. The system is fully erodable and can be
utilized as a powder, compressed into a tablet or cast as a film.
PROLOC is effective for both localized and systemic therapies. PROLOC
facilitates transmucosal drug delivery providing a convenient means for rapid
and direct local or systemic absorption and onset of therapeutic effects,
allowing lower dosages and resulting in fewer side effects.
For a free copy of the "PROLOC Bioadhesive Drug Delivery System" brochure,
contact Michael Trisch at 908-685-5317 (business inquiries), Susan Lydzinski,
908-685-5462; or Dr. Paul Foreman, 908-685-5456 (technical inquiries) or by
email to PROLOC@nstarch.com.
National Adhesives has been an integral part of the bioadhesive market since
the technology's inception. As the global leader in acrylic polymers for
transdermal drug delivery, National's DURO-TAK® pressure sensitive adhesives
are approved in over 40 unique commercial patches marketed in the Americas,
Australia, China, Europe, India, Japan and Korea. National Adhesives has more
than 35 years of experience and expertise in acrylic pressure sensitive
adhesives, technical service, regulatory support, and manufacturing capability
in both North America and Europe.
National Adhesives is a unit of National Starch and Chemical Company, which
had worldwide sales of $3.7 billion in 2006. National Adhesives offers hot
melt, liquid emulsion and solvent-borne solution adhesives to customers
worldwide. National Adhesives' products are based on polyurethane, acrylic,
rubber, ethylene vinyl acetate, epoxy, polyvinyl acetate and starch and
dextrin chemistries. National is headquartered in Bridgewater, NJ, and is a
member of the ICI Group, an Akzo Nobel company.
For more information about National Starch and Chemical
Company and its products, visit www.nationalstarch.com. You also are welcome
to visit our on-line newsroom by clicking on the News button.
National Starch and Chemical Company is dedicated to meeting the needs and
expectations of customers without compromising its commitment to
sustainability. National Starch supports sustainability through its continuous
efforts to improve the safety, health and environment of the communities in
which it operates.
For detailed information on National Starch's sustainability program, visit www.nationalstarch.com.